ClinicalTrials.gg
RecruitingNCT06828354Updated Apr 20, 2026

A Study of SHR-A1811 in Subjects With Ovarian Cancer

A Phase 3 interventional study of SHR-A1811 and Paclitaxel Injection in Ovarian Cancer, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Recruiting at 2 sites in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-20.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Ovarian Neoplasms by Jiangsu HengRui Medicine Co., Ltd. — 6 open to participants now, 6 under way, 4 of them phase 3. Ovarian Neoplasms · Jiangsu HengRui Medicine Co., Ltd..

Planned enrollment
5th of 16
300 · median 188
Started
2025
with 1 other
Phase 3
6 of 16
3 open now
Registered
14th of 16
by date

Among the 16 studies in Ovarian Neoplasms by Jiangsu HengRui Medicine Co., Ltd., this one is the 5th largest by planned enrollment, is one of 2 that started in 2025, is one of 6 in phase 3, and was the 14th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

6 of the 16 studies in Ovarian Neoplasms by Jiangsu HengRui Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Ovarian Neoplasms by Jiangsu HengRui Medicine Co., Ltd., or all of them as a file.
02

Study summary

This is an open-label study to evaluate the safety and efficacy of SHR-A1811 for injection in subjects with ovarian cancer.

03

Conditions studied

  • Ovarian Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subjects voluntarily joined the study and signed the forms (ICF).
  2. , as defined by v1.1.
  3. The Eastern Cancer Cooperative Group () performance status of 0 or 1.
  4. ≥ 12 weeks.

Exclusion criteria

Exclusion Criteria:

  1. Symptomatic, untreated or active central nervous system .
  2. Have uncontrolled or severe cardiovascular disease.
  3. With any active disease or history of autoimmune disease.
  4. Patients with active or .
  5. Severe infections prior to initiation of study treatment.
  6. Patients with active tuberculosis.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    SHR-A1811 group

    Drug: SHR-A1811

  • Active comparator
    Chemotherapy group

    Drug: Paclitaxel Injection · Drug: Doxorubicin Hydrochloride Liposome Injection · Drug: Gemcitabine Hydrochloride for Injection · Drug: Topotecan Hydrochloride for Injection

Interventions

06

What researchers measure

Primary outcomes

  1. Progression free survival (PFS)

    Time frame: From day 1 to 10 months.

Secondary outcomes

  1. Objective response rate (ORR)

    Time frame: From day 1 to 12 months.

  2. Disease control rate (DCR)

    Time frame: From day 1 to 12 months.

  3. Duration of response (DOR)

    Time frame: From day 1 to 12 months.

  4. Overall survival (OS)

    Time frame: From day 1 to 12 months.

  5. Response rate (RR)

    Time frame: From day 1 to 12 months.

  6. Adverse events (AEs)

    Time frame: From day 1 to 40 days after the last dose.

07

Study locations

2 of 2 sites recruiting
  • Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei 430030, China
    Recruiting
    • Ding Ma · Contactding_ma2022@163.com · 027-83663821
    • Ding Ma · Principal investigator
    • Qinglei Gao · Principal investigator
  • Qilu Hospital of Shandong University
    Jinan, Shandong 250012, China
    Recruiting
    • Beihua Kong · Contactkongbeihua@sdu.edu.cn · 18653199168
    • Beihua Kong · Principal investigator
    • Kun Song · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for May 2027, 26 months after the start.

Of 73 industry-sponsored phase 3 interventional studies under Ovarian Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 72. This study's planned 26 months is below that.

Counting every sponsor, half of 125 studies reached it within 59 months; a quarter within 37 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2025
First posted
Feb 14, 2025
StartActual
Mar 13, 2025
Primary completionEst.
May 2027
CompletionEst.
Dec 2027
Last update
Apr 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06828354
Responsible party
Sponsor
First posted
Feb 14, 2025
Start date
Mar 13, 2025
Primary completion
May 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Apr 20, 2026

Study contacts

Yuanchao Wang
Contact
yuanchao.wang@hengrui.com
0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab rezetecan

Start the discussion